RxDoctor Payments Data

Maria Oconer, MD

Internal Medicine · Lakeland, FLNPI 1770812372

Payments from drug & device makers

$579in general payments, 2019–2025

Across 26 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$202
  • AstraZeneca$153
  • Dexcom, Inc.$83
  • AbbVie$77
  • Pfizer$19
  • Boehringer Ingelheim$16
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$579100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$579 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$66,133
Medicare patients
149
Services billed
1,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide162$213,255
JardianceEmpagliflozin169$184,011
FarxigaDapagliflozin Propanediol114$105,256
EliquisApixaban103$94,092
MounjaroTirzepatide38$45,281
JanuviaSitagliptin Phosphate42$41,205
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog68$37,835
TrulicityDulaglutide17$25,193
RybelsusSemaglutide13$21,181
XareltoRivaroxaban21$18,664
LinzessLinaclotide12$13,363
Tresiba Flextouch U-200Insulin Degludec20$12,325
Breo ElliptaFluticasone/Vilanterol18$11,421
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,973
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$9,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$202$234,436175 claims
Boehringer IngelheimJardiance, Stiolto Respimat$16$193,262183 claims
AstraZenecaFarxiga$153$105,256114 claims
PfizerEliquis$19$94,092103 claims
Lilly USA, LLCMounjaro, Trulicity$16$70,47455 claims
AbbVieLinzess$77$13,36312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →